Integrated Advisors Network LLC Acquires 259 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Integrated Advisors Network LLC lifted its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 13.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,157 shares of the medical research company’s stock after acquiring an additional 259 shares during the period. Integrated Advisors Network LLC’s holdings in Quest Diagnostics were worth $297,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in DGX. Altshuler Shaham Ltd bought a new position in shares of Quest Diagnostics in the 4th quarter worth about $26,000. VisionPoint Advisory Group LLC raised its position in shares of Quest Diagnostics by 100.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after acquiring an additional 109 shares in the last quarter. BKM Wealth Management LLC bought a new position in shares of Quest Diagnostics in the 4th quarter worth about $29,000. Alaska Permanent Fund Corp raised its position in shares of Quest Diagnostics by 79.3% in the 4th quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock worth $33,000 after acquiring an additional 107 shares in the last quarter. Finally, Headinvest LLC bought a new stake in Quest Diagnostics in the 3rd quarter valued at about $36,000. 88.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DGX. SVB Leerink began coverage on Quest Diagnostics in a research report on Monday, February 26th. They issued a “market perform” rating and a $135.00 target price for the company. Leerink Partnrs reaffirmed a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, February 26th. StockNews.com raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. boosted their price objective on Quest Diagnostics from $152.00 to $155.00 and gave the stock a “neutral” rating in a report on Thursday, May 30th. Finally, Truist Financial boosted their price objective on Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, April 24th. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $146.67.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,760 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $140.00, for a total transaction of $246,400.00. Following the sale, the senior vice president now owns 13,435 shares in the company, valued at $1,880,900. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.79% of the company’s stock.

Quest Diagnostics Price Performance

Quest Diagnostics stock opened at $137.32 on Wednesday. Quest Diagnostics Incorporated has a 12 month low of $119.59 and a 12 month high of $145.62. The company has a current ratio of 0.97, a quick ratio of 0.89 and a debt-to-equity ratio of 0.59. The business’s 50 day simple moving average is $137.52 and its 200 day simple moving average is $133.66. The company has a market cap of $15.25 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 2.99 and a beta of 0.90.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.18. The firm had revenue of $2.37 billion for the quarter, compared to the consensus estimate of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The business’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.04 earnings per share. Sell-side analysts forecast that Quest Diagnostics Incorporated will post 8.79 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, July 22nd. Shareholders of record on Monday, July 8th will be given a dividend of $0.75 per share. The ex-dividend date is Monday, July 8th. This represents a $3.00 annualized dividend and a dividend yield of 2.18%. Quest Diagnostics’s dividend payout ratio is currently 40.38%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.